Compare
Emmaus Life Sciences, Inc. vs Prelude Therapeutics Inc vs Evommune, Inc. vs Tonix Pharmaceuticals Holding Corp.
| Latest fiscal year | Emmaus Life Sciences, Inc. EMMA | Prelude Therapeutics Inc PRLD | Evommune, Inc. EVMN | Tonix Pharmaceuticals Holding Corp. TNXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.45M | $12.14M | $13.00M | $13.11M |
| Revenue growth (YoY) | -25.2% | +73.4% | +85.7% | +29.8% |
| Gross margin | 93.1% | n/a | n/a | 49.3% (computed) |
| Operating margin | 1.9% | -861.3% | -623.6% | -959.1% |
| Net margin | -60.2% | -819.6% | -529.8% | -946.2% |
| Net income | -$7.49M | -$99.50M | -$68.87M | -$124.02M |
| EPS (Diluted) | -$0.12 | -$1.29 | -$11.22 | -$14.57 |
| Operating cash flow | -$11.0K | -$56.30M | -$76.44M | -$99.84M |
| Free cash flow | -$12.0K | -$56.37M | -$76.68M | -$103.21M |
| Cash & equivalents | $2.13M | $35.26M | $44.06M | $207.64M |
| Total assets | $21.44M | $141.31M | $224.95M | $277.17M |
| Total liabilities | $85.04M | $72.68M | $19.38M | $32.02M |
| Shareholders' equity | -$63.61M | $68.64M | $205.57M | $245.15M |
| Return on year-end equity | n/a | -145.0% | -33.5% | -50.6% |
| Shares outstanding | 70.19M | n/a | 31.52M | 12.79M |
Revenue, most recent five fiscal years
| Fiscal year | Emmaus Life Sciences, Inc. | Prelude Therapeutics Inc | Evommune, Inc. | Tonix Pharmaceuticals Holding Corp. |
|---|---|---|---|---|
| Latest | $12.45M Ended 2025-12-31 | $12.14M Ended 2025-12-31 | $13.00M Ended 2025-12-31 | $13.11M Ended 2025-12-31 |
| 1 year earlier | $16.65M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $10.09M Ended 2024-12-31 |
| 2 years earlier | $29.60M Ended 2023-12-31 | n/a | n/a | $7.77M Ended 2023-12-31 |
| 3 years earlier | $18.39M Ended 2022-12-31 | n/a | n/a | n/a |
| 4 years earlier | $20.61M Ended 2021-12-31 | n/a | n/a | n/a |